Seres Therapeutics initiated at H.C. Wainwright

Seres Therapeutics assumed with a Buy at H.C. Wainwright. H.C. Wainwright analyst Vernon Bernardino assumed coverage of Seres Therapeutics with a Buy rating and $16 price target. The company is “strongly positioned” in the race to apply a microbiome approach in immune-oncology, Bernardino tells investors in a research note. The company possesses a “differentiated, and in our view, potentially disruptive technology that we expect could generate long-term pipeline value,” says the analyst.

https://thefly.com/landingPageNews.php?id=2868513